Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye-catching 838.4% between 2020 and 2022. But the company is now stepping ...

Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to agency staff.

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months.

The S&P 500 Healthcare sector (XLV) experienced a rise in average short interest during November, moving from 1.97% to 2.12%.

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety ...

Moderna, Inc. is a biotechnology company specializing in the discovery and development of mRNA-based medicines. The company leverages its mRNA technology platform to address a broad range of diseases, ...